LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042

ConclusionFindings of this descriptive exploratory analysis suggest that pembrolizumab monotherapy should be considered as a standard first-line treatment option for PD-L1-positive advanced non-squamous NSCLC regardless of KRAS mutational status. These findings also suggest that a pembrolizumab-containing regimen is a clinically relevant comparator for studies of KRAS -targeted therapy given as first-line treatment of NSCLC. Table: LBA4With Any KRAS MutationWith KRAS G12C MutationWithout Any KRAS MutationPembro Mono-therapy (N  = 30)Chemo-therapy (N = 39)Pembro Mono-therapy (N = 12)Chemo-therapy (N = 17)Pembro Mono-therapy (N = 127)Chemo-therapy (N = 105)ORR, % (95% CI)56.7 (37.4-74.5)18.0 (7.5-33.5)66.7 (34.9-90.1)23.5 (6.8-49.9)29.1 (21.4-37.9)21.0 (13.6-30.0)PFS, median, mo (95% CI)12 (8-NR)6 (4 -9)15 (10-NR)6 (4-8)6 (4-7)6 (6-8)PFS, HR (95% CI)0.51 (0.29-0.87)0.27 (0.10-0.71)1.00 (0.75-1.34)OS, median, mo (95% CI)28 (23-NR)11 (7-25)NR (23-NR)8 (5-NR)15 (12-24)12 (11-18)OS, HR (95% CI)0.42 (0.22-0.81)0.28 (0.09-0.86)0.86 (0.63-1.18)Clinical trial identificationKEYNOTE-042; NCT02220894.Editorial acknowledgementJoanne Tomassini and Melanie Leiby, both of Merck& Co., Inc., Kenilworth, NJ, for writing support.Legal entity responsible for the studyMerck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.FundingMerck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.DisclosureR.S. Herbst: ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research